METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
1 .- 23 . (canceled)
24 . A method of treating a patient having a tumor disease that expresses a tumor antigen encoded by a nucleic acid according to SEQ ID NO: 1 or a variant of said nucleic acid sequence, wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds the tumor antigen.
25 . The method of claim 24 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody.
26 . The method of claim 24 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme.
27 . The method of claim 24 , wherein the tumor disease is selected from the group consisting of ovarian cancer, ovarian adenocarcinoma, ovarian teratocarcinoma, lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung carcinoma, lung adenocarcinoma, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, head and neck cancer, malignant pleomorphic adenoma, sarcoma, synovial sarcoma, synovial carcinosarcoma, bile duct cancer, renal cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, uterine cancer, cancer of the urinary bladder, papillary carcinoma, colon cancer, transitional cell carcinoma small bowel cancer, cancer of the ileum, small bowel adenocarcinoma, adenocarcinoma of the ileum, testicular embryonal carcinoma, placental choriocarcinoma, cervical cancer, testicular cancer testicular seminoma, testicular teratoma, embryonic testicular cancer, and the metastatic forms thereof.
28 . The method of claim 27 , wherein when the tumor disease is selected from ovarian cancer, lung cancer, metastatic ovarian cancer, and metastatic lung cancer.
29 . A method of treating a patient having a tumor disease diagnosed by detecting the presence or the quantity of a tumor antigen comprising an amino acid sequence encoded by a nucleic acid sequence of SEQ ID NO: 1 in a biological sample taken from the patient, wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds the tumor antigen.
30 . The method of claim 29 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody.
31 . The method of claim 29 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme.
32 . The method of claim 29 , wherein the tumor disease is selected from the group consisting of ovarian cancer, ovarian adenocarcinoma, ovarian teratocarcinoma, lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung carcinoma, lung adenocarcinoma, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, head and neck cancer, malignant pleomorphic adenoma, sarcoma, synovial sarcoma, synovial carcinosarcoma, bile duct cancer, renal cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, uterine cancer, cancer of the urinary bladder, papillary carcinoma, colon cancer, transitional cell carcinoma small bowel cancer, cancer of the ileum, small bowel adenocarcinoma, adenocarcinoma of the ileum, testicular embryonal carcinoma, placental choriocarcinoma, cervical cancer, testicular cancer testicular seminoma, testicular teratoma, embryonic testicular cancer, and the metastatic forms thereof.
33 . The method of claim 32 , wherein when the tumor disease is selected from ovarian cancer, lung cancer, metastatic ovarian cancer, and metastatic lung cancer.
34 . The method of claim 29 , wherein detecting the presence or the quantity of the tumor antigen comprises detecting the amount of a complex formed between SEQ ID NO: 1 and at least one oligonucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:7, wherein an increased amount of the complex in the biological sample of the patient as compared to a normal sample of an individual without a tumor disease indicates the patient has the tumor disease.